Satellos Bioscience Inc.
MSLE evidence brief
What we can confirm
- Market Cap:
- $206.9M
What it means
What to watch
Prepared research question
What matters most for MSLE—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · MSLE
Satellos Bioscience Inc. is a clinical-stage biotechnology company developing forazapadin (formerly SAT-3247), an oral small-molecule AAK1 inhibitor for degenerative muscle diseases, with its Phase 2 BASECAMP trial in Duchenne muscular dystrophy fully enrolled and data expected in Q1 2027.
Key risk: Single-asset dependency
Market Cap
$206.9M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Dec 31, 2025.
Tracking 3 clinical trials for Satellos Bioscience Inc..
Satellos Bioscience Inc. is a clinical-stage biotechnology company developing forazapadin (formerly SAT-3247), an oral small-molecule AAK1 inhibitor for degenerative muscle diseases, with its Phase 2 BASECAMP trial in Duchenne muscular dystrophy fully enrolled and data expected in Q1 2027.
- Lead drug candidate forazapadin (SAT-3247) is an orally administered small-molecule AAK1 inhibitor designed to restore muscle regeneration [news · published 2026-09-09].
- Phase 2 BASECAMP trial in ambulatory boys 7–10 years with Duchenne muscular dystrophy completed enrollment in September 2026; data expected Q1 2027 [news · published 2026-09-30].
- Cash available of $69.9M (Cdn $97.5M) as of Q1 2026 provides runway through 2027 [news · published 2026-05-15].
- U.S. composition-of-matter patent granted for forazapadin, providing protection through September 6, 2044 [news · published 2026-10-05].
- TRAILHEAD study initiated in the U.S. in adults aged 16–25 years [news · published 2026-05-15].
What works
- Completed enrollment in the Phase 2 BASECAMP trial on schedule, demonstrating execution capability in a rare-disease setting [news · published 2026-09-30].
- Strong cash position ($69.9M as of Q1 2026) provides financial runway through 2027, reducing near-term dilution risk [news · published 2026-05-15].
- Granted a U.S. composition-of-matter patent for forazapadin, offering intellectual property protection through 2044 [news · published 2026-10-05].
What to weigh
- The company is pre-revenue and clinical-stage, with no approved products or disclosed partnership revenue [news · published 2026-05-15].
- Duchenne muscular dystrophy is a competitive space with multiple approved therapies and ongoing trials, posing market-entry challenges [competitor_trial].
- BASECAMP data are not yet available; the program's success hinges on positive efficacy and safety results expected in Q1 2027 [news · published 2026-09-30].
From the filings
Quoted directly from source documents.
Lead drug candidate forazapadin is an oral small-molecule AAK1 inhibitor for muscle regeneration.
“orally administered, small molecule drug candidate designed to restore muscle regeneration that was previously known as SAT-3247”
News · September 9, 2026
BASECAMP Phase 2 trial enrollment completed.
“enrollment has been completed for BASECAMP, the company’s Phase 2 clinical trial evaluating forazapadin for the treatment of Duchenne muscular dystrophy”
News · September 30, 2026
Cash available provides runway through 2027.
“Current cash available of $69.9M (Cdn $97.5M) provides runway through 2027”
News · May 15, 2026
U.S. composition-of-matter patent granted for forazapadin.
“the United States Patent and Trademark Office has issued U.S. Patent No. 12,747,245, entitled “AP2 associated kinase 1 inhibitors and uses”
News · October 5, 2026
Catalyst timeline
- 2024-08-21 · Phase 1 start — Phase 1 randomized, double-blind, placebo-controlled SAD/MAD and food effect study in healthy volunteers and DMD participants.
- 2025-08-20 · Phase 2 start (open-label long-term follow-up) — Open-label long-term follow-up study of SAT-3247 in DMD patients who participated in SAT-3247-CL-101.
- 2025-12-08 · Phase 2a start (randomized, double-blind, placebo-controlled dose comparison) — Phase 2a randomized, double-blind, placebo-controlled dose comparison and exploratory efficacy study in ambulatory DMD patients.
Risks & what to watch (3)›
Key risks
- Single-asset dependency — All clinical-stage programs center on forazapadin; no diversified pipeline [news · published 2026-09-09].
- Competitive DMD landscape — Multiple approved therapies and ongoing competitor trials in Duchenne muscular dystrophy [competitor_trial].
- Data-dependent valuation — Phase 2 BASECAMP data due Q1 2027; negative results would severely impact outlook [news · published 2026-09-30].
What to watch
- BASECAMP Phase 2 data release expected in Q1 2027 [news · published 2026-09-30].
- TRAILHEAD study enrollment and early data in adults aged 16–25 [news · published 2026-05-15].
- Cash burn rate and any new financing activities given $69.9M runway through 2027 [news · published 2026-05-15].
Sources: Catalysts · Competitor trials · News · Generated October 12, 2026 · How we verify sources →
Run Satellos Bioscience Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Satellos Bioscience Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Short Interest
- % of float
- -
- Days to cover
- —
- Shares short
- -
- Daily short volume (Jun 23, 2026)
- 57.8%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
MSLE short interestFrequently asked questions
What is the AI investment thesis for Satellos Bioscience Inc.?
Satellos Bioscience Inc. is a clinical-stage biotechnology company developing forazapadin (formerly SAT-3247), an oral small-molecule AAK1 inhibitor for degenerative muscle diseases, with its Phase 2 BASECAMP trial in Duchenne muscular dystrophy fully enrolled and data expected in Q1 2027.
Who is the CEO of Satellos Bioscience Inc.?
Mr. Francis Gleeson B.B.A. M.B.A is the chief executive officer of Satellos Bioscience Inc. (MSLE).
Where is Satellos Bioscience Inc. headquartered?
Satellos Bioscience Inc. (MSLE) is headquartered in Toronto, ON, Canada.
What therapeutic areas does Satellos Bioscience Inc. focus on?
Satellos Bioscience Inc. develops therapies across Oncology, Rare Disease.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.